Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 19Docetaxel 17Cetuximab 12Carboplatin 12Radiotherapy 11Magnetic Resonance Spectroscopy 10Biopsy 10pembrolizumab 9Paclitaxel 9Radiotherapy, Intensity-Modulated 8Immunohistochemistry 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiotherapy, Conformal 5Radiosurgery 5Gene Expression Profiling 5Fluorodeoxyglucose F18 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Polymerase Chain Reaction 4Nivolumab 4Bevacizumab 4trastuzumab deruxtecan 3sargramostim 3bicalutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × talactoferrin alfa × Head & Neck × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡